Executive Performance

Why These Combine

Five compounds aimed at three different things — acetylcholine supply, cortisol control and cellular energy — for someone whose day is long, decision-heavy and stressful. The population mismatch that runs through this whole site is largest here, so take the trials one at a time. Citicoline at 500 mg is the dose from the best healthy-adult trial available: 100 adults aged 50–85 with age-associated memory impairment improved on episodic and composite memory after 12 weeks against placebo (Nakazaki 2021), and 250–500 mg a day improved attention and psychomotor speed in 75 healthy adolescent males over 28 days (McGlade 2019); the Focus & Flow stack uses the lower dose. Ashwagandha's cortisol evidence is the strongest fit for the brief: 300 mg twice daily for 60 days lowered every stress scale and serum cortisol in 64 chronically stressed adults (Chandrasekhar 2012), and 240 mg a day lowered anxiety ratings and morning cortisol in 60 stressed healthy adults (Lopresti 2019). Magnesium L-threonate is the component whose marketing has run furthest ahead of its data. The brain-magnesium and synapse-density claims come from the developers' own rodent work, as the trial paper itself states; the one placebo-controlled human trial randomised 44 adults aged 50–70 with cognitive impairment to MMFS-01 — a magnesium L-threonate compound trademarked as ClariMem, tested by the company that developed it — or placebo for 12 weeks and found a composite cognitive score improved with a large effect size (d=0.91), while sleep and anxiety outcomes could not be judged because of placebo effects (Liu 2016). A 30-day trial in 109 healthy Chinese adults used a combined threonate-plus-phosphatidylserine-plus-vitamins formula, so it cannot say what the magnesium did on its own (Zhang 2022). ALCAR's meta-analysis benefit — effect size 0.20 — is in mild cognitive impairment and early Alzheimer's at 1.5–3 g a day (Montgomery 2003), three to six times the 500 mg here, and a randomised trial in women on taxane chemotherapy found it made nerve damage worse (Hershman 2018). Omega-3 at this dose has a healthy-young-adult trial behind it, but only in people whose intake was low (Stonehouse 2013). Compared with Focus & Flow this is heavier, costlier and adds cortisol and magnesium components; compared with Stress Shield it keeps the ashwagandha and adds cholinergic and energy compounds; Memory & Recall is the better choice if recall rather than stamina is the complaint. Verdict: citicoline and ashwagandha earn their places; the threonate is a reasonable trial if you accept that its evidence is one small study in impaired adults; ALCAR is under-dosed relative to its own evidence and carries a real caution — and the existing advice to introduce one compound at a time is the most important line on this page.

• A lighter version of the cholinergic core — the Focus & Flow stack at 250 mg citicoline→
• If cortisol is the whole problem, the Stress Shield stack is built around it→
• Citicoline dosage by goal — which trial used which dose→

References

1. 1.Nakazaki 2021, J Nutr — 100 healthy adults aged 50–85 with age-associated memory impairment, randomised double-blind: citicoline 500 mg/day for 12 weeks improved episodic memory (paired-associate test 0.15 vs 0.06, p=0.0025) and composite memory (3.78 vs 0.72, p=0.0052) versus placebo.
2. 2.McGlade 2019, J Atten Disord — 75 healthy adolescent males randomised to 250 or 500 mg citicoline or placebo for 28 days: improved attention (p=0.02) and psychomotor speed (p=0.03).
3. 3.Chandrasekhar 2012, Indian J Psychol Med — 64 adults with chronic stress, randomised double-blind: 300 mg full-spectrum ashwagandha root extract twice daily for 60 days reduced all stress-scale scores (p<0.0001) and serum cortisol (p=0.0006) versus placebo.
4. 4.Lopresti 2019, Medicine (Baltimore) — 60 stressed healthy adults, 60 days: 240 mg standardised ashwagandha extract once daily reduced Hamilton Anxiety scores (p=.040) and morning cortisol (p<.001) versus placebo; no adverse events.
5. 5.Liu 2016, J Alzheimers Dis — 44 adults aged 50–70 with cognitive impairment, randomised double-blind: MMFS-01 (a magnesium L-threonate compound, n=23) vs placebo (n=21) for 12 weeks improved overall cognitive ability (p=0.003, Cohen's d=0.91) and reduced cognitive fluctuation; effects on sleep and anxiety could not be determined because of strong placebo effects. (small, impaired population, run by the compound's developer (Neurocentria); the sole placebo-controlled trial of this form)
6. 6.Zhang 2022, Nutrients — 109 healthy Chinese adults aged 18–65, double-blind: 2 g/day of a magnesium L-threonate + phosphatidylserine + vitamins C and D formula for 30 days improved all five Clinical Memory Test subscores versus placebo, more so in older participants. (combined formula — cannot isolate the magnesium effect)
7. 7.Montgomery 2003, Int Clin Psychopharmacol — Meta-analysis of double-blind placebo-controlled trials of 3–12 months at 1.5–3.0 g/day in mild cognitive impairment and early Alzheimer's disease: integrated effect size 0.201 (95% CI 0.107–0.295); well tolerated. (clinical populations at three to six times the dose used here)
8. 8.Hershman 2018, J Natl Cancer Inst — SWOG S0715: 409 women on adjuvant taxane chemotherapy, ALCAR 1000 mg three times daily vs placebo for 24 weeks — significantly worse neuropathy scores (−1.39 points, 95% CI −2.48 to −0.30, p=.01), still evident at two years. (randomised trial showing harm in a specific population — the basis of the chemotherapy warning)
9. 9.Stonehouse 2013, Am J Clin Nutr — 176 healthy adults aged 18–45 with low habitual DHA intake: 1.16 g DHA/day for 6 months improved reaction times of episodic and working memory versus placebo.